Christiane Angermann Angermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1192998/publications.pdf

Version: 2024-02-01

471509 434195 1,614 31 17 31 citations h-index g-index papers 32 32 32 1725 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	30.7	341
2	Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure. Circulation: Heart Failure, 2012, 5, 25-35.	3.9	209
3	Pulmonary artery pressureâ€guided therapy in ambulatory patients with symptomatic heart failure: the <scp>CardioMEMS E</scp> uropean <scp>M</scp> onitoring <scp>S</scp> tudy for <scp>H</scp> eart <scp>F</scp> ailure (<scp>MEMSâ€HF</scp>). European Journal of Heart Failure, 2020, 22, 1891-1901.	7.1	142
4	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health, 2020, 8, e411-e422.	6.3	104
5	Nurseâ€coordinated collaborative disease management improves the quality of guidelineâ€recommended heart failure therapy, patientâ€reported outcomes, and left ventricular remodelling. European Journal of Heart Failure, 2015, 17, 442-452.	7.1	103
6	Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clinical Research in Cardiology, 2017, 106, 436-443.	3.3	85
7	Depression, Anxiety, and Cognitive Impairment. Current Heart Failure Reports, 2018, 15, 398-410.	3.3	65
8	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
9	Sodium–glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834.	7.1	60
10	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORTâ€HF): rationale for and design of a global registry. European Journal of Heart Failure, 2015, 17, 527-533.	7.1	52
11	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	6.1	51
12	Comparative Potential of the 2-Item Versus the 9-Item Patient Health Questionnaire to Predict Death or Rehospitalization in Heart Failure. Circulation: Heart Failure, 2015, 8, 464-472.	3.9	41
13	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clinical Research in Cardiology, 2018, 107, 991-1002.	3.3	37
14	Prognostic potential of midregional proâ€adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. European Journal of Heart Failure, 2017, 19, 1166-1175.	7.1	30
15	Heart and brain interactions. Herz, 2021, 46, 138-149.	1.1	24
16	Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression. Clinical Research in Cardiology, 2019, 108, 244-253.	3.3	23
17	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. International Journal of Cardiology, 2016, 203, 69-73.	1.7	22
18	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234.	2.2	22

#	Article	IF	Citations
19	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the ⟨scp⟩REPORTâ€HF⟨/scp⟩ registry. European Journal of Heart Failure, 2022, 24, 645-652.	7.1	18
20	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	1.7	17
21	Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. Clinical Research in Cardiology, 2018, 107, 95-107.	3.3	15
22	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 349-359.	4.1	14
23	A functional variant of the neuropeptide S receptorâ€1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (<scp>INH</scp>) Study. European Journal of Heart Failure, 2017, 19, 314-323.	7.1	13
24	Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. Journal of the American Heart Association, 2021, 10, e017822.	3.7	13
25	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from	4314 rgBT 7.1	/Overlock 1
26	Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling. International Journal of Cardiology, 2017, 232, 199-207.	1.7	11
27	Sexâ€specific bimodal clustering of left ventricular ejection fraction in patients with acute heart failure. ESC Heart Failure, 2022, 9, 786-790.	3.1	8
28	The trialist's perspective: what do you need to prove for remote monitoring devices to be approved?. European Heart Journal Supplements, 2019, 21, M57-M60.	0.1	5
29	Clinical characteristics, treatment and survival in patients with systolic heart failure — Comparative assessment of a Chinese and a German cohort. International Journal of Cardiology, 2014, 176, 1388-1390.	1.7	4
30	Dynamics of Left Ventricular Myocardial Work in Patients Hospitalized for Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 1393-1403.	1.7	4
31	Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. Clinical Research in Cardiology, 2023, 112, 868-879.	3.3	4